Abstract |
Androgen receptor (AR)- and glucocorticoid receptor (GR)- mediated signaling play opposite roles in prostate tumorigenesis: AR promotes prostate carcinoma (PC) development, whereas GR acts as a tumor suppressor. Compound A (CpdA) is a stable analogue of an aziridine precursor from the African shrub Salsola tuberculatiformis Botschantzev. It was shown recently that, in model cells, CpdA inhibits AR function and strongly enhances anti-inflammatory function of GR. We determined the effects of CpdA in prostate cells with different AR/GR status: (a) RWPE-1 cells (AR(low)/GR(low)), (b) PC3 and DU145 cells (GR(+)/AR(-)), (c) LNCaP cells (GR(-)/AR(+)), and (d) LNCaP-GR cells expressing both receptors. Similar to steroid hormones, CpdA induces nuclear translocation of both receptors in prostate cells. Despite this, CpdA inhibits DNA-binding and transactivation potential of AR. In addition, CpdA inhibits GR-mediated transactivation but induces GR transrepression via inhibition of several transcription factors, including nuclear factor-kappaB, AP-1, Ets-1, Elk-1, SRF, CRE/ATF, and NFATc. CpdA strongly decreases growth and induces caspase-dependent apoptosis in highly malignant PC3 and DU145 cells and in other AR/GR-expressing PC cells. The cytostatic effect of CpdA is receptor dependent: down-regulation of GR or AR expression drastically attenuates CpdA-induced PC cell growth inhibition. Finally, virtual docking analysis indicates that CpdA shares binding cavities in AR and GR ligand-binding domains with corresponding hormones and forms hydrogen bonds (H-bond) with the same amino acids that are involved in H-bond formation during steroid binding. Overall, our data suggest that CpdA is a unique dual-target steroid receptor modulator that has a high potential for PC therapy.
|
Authors | Alexander Yemelyanov, Jennifer Czwornog, Lajos Gera, Sonali Joshi, Robert T Chatterton Jr, Irina Budunova |
Journal | Cancer research
(Cancer Res)
Vol. 68
Issue 12
Pg. 4763-73
(Jun 15 2008)
ISSN: 1538-7445 [Electronic] United States |
PMID | 18559523
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- 2-(4-acetoxyphenyl)-2-chloro-N-methylethylamine
- AR protein, human
- Acetates
- Androgen Antagonists
- Androgens
- Ethylamines
- RNA, Small Interfering
- Receptors, Androgen
- Receptors, Glucocorticoid
- Transcription Factors
- Luciferases
- Prostate-Specific Antigen
- Tyramine
|
Topics |
- Acetates
(chemical synthesis, pharmacology)
- Androgen Antagonists
(pharmacology)
- Androgens
(pharmacology)
- Apoptosis
(drug effects)
- Blotting, Western
- Cell Proliferation
(drug effects)
- Colony-Forming Units Assay
- Electrophoretic Mobility Shift Assay
- Ethylamines
(chemical synthesis, pharmacology)
- Humans
- Hydrogen Bonding
- Luciferases
(metabolism)
- Male
- Prostate-Specific Antigen
(metabolism)
- Prostatic Neoplasms
(drug therapy, genetics, metabolism)
- RNA, Small Interfering
(pharmacology)
- Radioligand Assay
- Receptors, Androgen
(genetics, metabolism)
- Receptors, Glucocorticoid
(agonists, genetics, metabolism)
- Transcription Factors
(antagonists & inhibitors, metabolism)
- Transcription, Genetic
- Transcriptional Activation
- Transfection
- Tumor Cells, Cultured
- Tyramine
(analogs & derivatives)
|